In this segment of her interview, Kimball discusses phase 2b tulisokibart data in hidradenitis suppurativa and the rationale for targeting TL1A.
Alexa Kimball, MD, MPH
Advertisement
Alexa B. Kimball, MD, MPH, serves as a professor of dermatology at Harvard Medical School as well as president and CEO of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center.
Articles by Alexa Kimball, MD, MPH
This interview highlights phase 3 findings on sonelokimab for individuals with hidradenitis suppurativa (HS).
This Q&A highlights Dr. Alexa B. Kimball's responses to questions on the FDA approval of secukinumab for pediatric patients with hidradenitis suppurativa (HS).
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
New Treatment Option for Adults and Pediatric Patients Weighing 30 kg (66 lbs) or More With Symptomatic Obstructive Hypertrophic Cardiomyopathy
2
Cardiac Health Indicators Improve Following CCM Implantation in Heart Failure
3
SCD-PED Tied to Higher Survival in Septic AKI, With Stuart Goldstein, MD
4
FDA Label Change Drops Mandatory TB Screening for Risankizumab
5